Roivant Sciences (ROIV) Capital Expenditures (2020 - 2025)

Roivant Sciences has reported Capital Expenditures for 6 years, with the latest figure at $6.9 million in Q4 2025.

• For the quarter ending Q4 2025, Capital Expenditures rose 83.42% year-over-year to $6.9 million; the trailing twelve-month figure through Dec 2025 stood at $22.6 million (up 233.52% YoY), and the FY2026 full-year result was $8.2 million, up 78.5% from the prior year.
• Capital Expenditures for Q4 2025 stood at $6.9 million, down from $7.8 million in the prior quarter.
• The five-year high for Capital Expenditures was $11.2 million in Q4 2021, with the low at $275000.0 in Q3 2023.
• Historically, Capital Expenditures has averaged $4.3 million across 5 years, with a median of $3.1 million in 2022.
• Annual changes were most pronounced in 2023 — Capital Expenditures slumped 94.6% — and 2025, when it soared 687.95%.
• Roivant Sciences' Capital Expenditures stood at $11.2 million in 2021, then declined by 0.94% to $11.1 million in 2022, then tumbled by 90.67% to $1.0 million in 2023, then surged by 266.7% to $3.8 million in 2024, then soared by 83.42% to $6.9 million in 2025.
• The last three Capital Expenditures figures came in at $6.9 million (Q4 2025), $7.8 million (Q3 2025), and $4.0 million (Q2 2025), per Business Quant data.